U.S. Beverage Stock News

We wouldn't blame Agnico Eagle Mines Limited ( NYSE:AEM ) shareholders if they were a little worried about the fact...

NasdaqCM:VFF 1 Year Share Price vs Fair Value Explore Village Farms International's Fair Values from the Community and...

NasdaqCM:CREX 1 Year Share Price vs Fair Value Explore Creative Realities's Fair Values from the Community and select...

NasdaqGM:HROW 1 Year Share Price vs Fair Value Explore Harrow's Fair Values from the Community and select yours Harrow...

NasdaqCM:BFC 1 Year Share Price vs Fair Value Explore Bank First's Fair Values from the Community and select yours Bank...

With a median price-to-sales (or "P/S") ratio of close to 2.7x in the Medical Equipment industry in the United States...

Those following along with Sonos, Inc. ( NASDAQ:SONO ) will no doubt be intrigued by the recent purchase of shares by...

NYSE:DAVA 1 Year Share Price vs Fair Value Explore Endava's Fair Values from the Community and select yours Howard...

NYSE:GDOT 1 Year Share Price vs Fair Value Explore Green Dot's Fair Values from the Community and select yours Green...

NYSE:ZIP 1 Year Share Price vs Fair Value Explore ZipRecruiter's Fair Values from the Community and select yours...

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

NYSE:GDOT 1 Year Share Price vs Fair Value Explore Green Dot's Fair Values from the Community and select yours Green...

Key Insights Significant control over Gamehaus Holdings by individual investors implies that the general public has...

NYSE:NX 1 Year Share Price vs Fair Value Explore Quanex Building Products's Fair Values from the Community and select...

NasdaqGM:MNDO 1 Year Share Price vs Fair Value Explore MIND C.T.I's Fair Values from the Community and select yours...

Moderna recently lowered its 2025 revenue guidance by US$300 million due to a shift in timing for U.K. COVID-19 vaccine shipments, moving that revenue into early 2026, and released second-quarter results showing a year-over-year decline in revenue to US$142 million and a net loss of US$825 million. While the U.K. shipment timing reduces near-term visibility, the total value of Moderna's long-term contract with the U.K. remains unchanged, highlighting the continuing demand for its COVID-19...

IDEX Corporation recently reported its second quarter 2025 financial results, announced the pursuit of tuck-in M&A opportunities, and revised both its full-year and third quarter guidance, with updated buyback activity through June 30, 2025. An interesting development is IDEX’s renewed emphasis on opportunistic acquisitions and capital allocation discipline, signaled during its earnings call amid a changing macroeconomic landscape and continued trade policy uncertainty. We’ll now examine how...

In July 2025, Terex Corporation announced new earnings guidance for the full year and updated investors on recent share repurchases, while also reporting its second quarter results showing increased sales but a large drop in net income compared to the prior year. A key insight from these announcements is that Terex completed a major share buyback program and reduced its loan interest costs, signaling a clear focus on capital structure efficiency and shareholder returns. Now, we'll explore...

Driven Brands Holdings Inc. recently reported its second-quarter results for 2025, with revenue reaching US$551.0 million and net income rising to US$47.56 million compared to a year ago, while also reiterating its full-year revenue guidance of US$2.05 billion to US$2.15 billion. Despite showing year-over-year growth, analyst downgrades to future earnings per share forecasts reflected caution regarding the company's longer-term profit potential. We’ll examine how the post-earnings analyst...

eXp World Holdings recently reported second quarter results, revealing sales of US$1,308.88 million but a net loss of US$2.29 million, along with an announcement of a US$0.05 per share dividend to be paid on August 29, 2025, following share repurchases during the quarter. This combination of declining profitability, ongoing share buybacks, and continued dividend payments has prompted investor focus on the company’s ability to sustain its current payout amid shifting earnings trends. We'll...

Home Depot is set to report its second-quarter 2025 earnings on August 19, with expectations for continued resilience in spring-related and smaller home improvement projects as well as the Pro segment, despite ongoing pressure on larger discretionary projects due to elevated interest rates. Early trends from the first half of the year indicate steady customer engagement and modest growth in higher-value transactions, which may help balance out the softer spending in large-scale...

Hyatt Hotels Corporation recently announced its second quarter 2025 earnings, highlighting revenue growth to US$1.81 billion and net loss of US$3 million, alongside a revised full-year net income forecast between US$135 million and US$165 million. The company also expanded its loyalty program through participation with Bunkhouse Hotels and maintained its quarterly dividend, underscoring a continued focus on brand and guest experience enhancement despite recent margin pressures. We'll examine...

Eagle Materials Inc. recently declared a quarterly cash dividend of US$0.25 per share, payable on October 16, 2025, with a record date of September 15, and announced the resignation of director Richard R. Stewart following its annual shareholder meeting on August 4, 2025. Shareholders approved a proposal to declassify the Board of Directors, marking a governance shift that heightens board accountability and refreshment. We'll explore how the board declassification and dividend decision could...

Earlier this month, Certara, Inc. reported its second quarter 2025 financial results, highlighted by a year-over-year sales increase to US$104.57 million and a narrowing net loss, and announced that the European Medicines Agency had formally qualified its Simcyp Simulator for regulatory submissions across the EU. This regulatory first for Certara’s Simcyp software enables more efficient drug submission processes and could accelerate biosimulation adoption among pharmaceutical companies...